Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a... IntroductionWith the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India.MethodsAn expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as “consensus.”ResultsDegarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options.ConclusionThis article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus

Download PDF
23 pages

Loading next page...
 
/lp/springer-journals/sequencing-of-systemic-therapies-in-the-management-of-advanced-x0pw0y57vU
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00181-1
Publisher site
See Article on Publisher Site

Abstract

IntroductionWith the availability of an increasing number of therapeutic options for advanced prostate cancer (APC), optimal sequencing and combination of therapies have emerged to be the areas of challenges. In the Indian context, there is a dearth of consensus recommendations to guide clinicians regarding optimal sequencing of therapy in APC management. A Delphi-based consensus regarding optimal therapy sequencing in APC management was developed by an expert panel of medical oncologists from across India.MethodsAn expert scientific committee of 11 medical oncologists and an expert panel of 53 medical oncologists from India constituted the panel for the Delphi consensus. In the first phase, a questionnaire with 41 clinical statements was developed in several critical controversial areas in APC treatment. In the second phase, 29 clinical statements were reworked and sent to eight experts to obtain their opinions on best practices. The consensus ratings were based on a 9-point Likert scale. Based on the overall response, statements with a mean score of ≥ 7 with 1 outlier were considered as “consensus.”ResultsDegarelix was the preferred androgen deprivation therapy (ADT). While ADT plus docetaxel was the preferred option for metastatic castrate-sensitive/naïve prostate cancer patients with high-volume disease, ADT with abiraterone was the preferred choice for low-volume disease. Docetaxel was the preferred first-line treatment option in men who received ADT alone in the castrate-sensitive/naïve setting. For patients progressing on or after docetaxel for metastatic castrate-resistant prostate cancer (without prior abiraterone or enzalutamide), the experts reached a consensus on the use of enzalutamide as the preferred second-line treatment option. No consensus was reached for the third-line treatment options.ConclusionThis article is intended to serve as a guide to help clinicians discuss with their patients as part of the shared and multidisciplinary decision-making for improved APC management in India.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 1, 2022

Keywords: Advanced prostate cancer; Androgen deprivation therapy; Castrate-sensitive prostate cancer; Castrate-resistant prostate cancer; Consensus; Delphi; India

References

  • Novel therapies are changing treatment paradigms in metastatic prostate cancer
    Powers, E; Karachaliou, GS; Kao, C; Harrison, MR; Hoimes, CJ; George, DJ
  • Advanced prostate cancer: treatment advances and future directions
    Swami, U; McFarland, TR; Nussenzveig, R; Agarwal, N
  • Prostate radiotherapy in India: evolution, practice and challenges in the 21st century
    Murthy, V; Mallick, I; Arunsingh, M; Gupta, P
  • Navigating the evolving therapeutic landscape in advanced prostate cancer
    Crawford, ED; Petrylak, D; Sartor, O
  • Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis
    He, L; Fang, H; Chen, C; Wu, Y; Wang, Y; Ge, H
  • A clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: guiding principles for treatment selection and perspectives on research
    Laccetti, AL; Morris, MJ; Kantoff, PW
  • Sorting through the maze of treatment options for metastatic castration-sensitive prostate cancer
    Schulte, B; Morgans, AK; Shore, ND; Pezaro, C
  • Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
    Saad, F; Efstathiou, E; Attard, G; Flaig, TW; Franke, F; Goodman, OB
  • Is there a role for immunotherapy in prostate cancer?
    Rizzo, A; Mollica, V; Cimadamore, A; Santoni, M; Scarpelli, M; Giunchi, F
  • Microbiota and prostate cancer
    Rizzo, A; Santoni, M; Mollica, V; Fiorentino, M; Brandi, G; Massari, F
  • The human gastrointestinal microbiota and prostate cancer development and treatment
    Sha, S; Ni, L; Stefil, M; Dixon, M; Mouraviev, V
  • The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer
    Mollica, V; Rizzo, A; Massari, F
  • Controversial issues in the management of patients with advanced prostate cancer: results from a Canadian consensus forum
    Saad, F; Canil, C; Finelli, A; Hotte, SJ; Malone, S; Shayegan, B
  • Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
    Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A
  • Clinical consensus statement development manual
    Rosenfeld, RM; Nnacheta, LC; Corrigan, MD
  • Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment
    Hahn, AW; Higano, CS; Taplin, M; Ryan, CJ; Agarwal, N
  • Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States
    George, DJ; Sartor, O; Miller, K; Saad, F; Tombal, B; Kalinovsky, J
  • Gonadotropin-releasing hormone: an update review of the antagonists versus agonists
    Poppel, HV; Klotz, L
  • Degarelix versus goserelin plus bicalutamide in the short-term relief of lower urinary tract symptoms in prostate cancer patients: results of a pooled analysis
    Mason, M; Richaud, P; Bosnyak, Z; Malmberg, A; Neijber, A
  • Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
    Iversen, P; Damber, J; Malmberg, A; Persson, BE; Klotz, L
  • Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
    Hosseini, SA; Rajabi, F; Akbari Sari, A; Ayati, M; Heidari, S; Ghamary, F
  • A randomized controlled trial to determine the effect of triptorelin on reduction of prostate volume preradiotherapy compared with standard therapy(goserelin)
    Bahl, A; Challapalli, A; Masson, S; Hilman, S; Hurley, K; Persad, R
  • Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: exploratory analysis of a randomized controlled trial
    Higano, CS; Crawford, ED; Shore, ND
  • Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
    Clinton, TN; Woldu, SL; Raj, GV
  • Is high-dose leuprorelin acetate effective and safe in Asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial
    Lee, S; Lee, H; Kim, SW; Lee, ES; Hong, SJ; Kim, CS
  • Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase 3 E3805 CHAARTED Trial
    Kyriakopoulos, CE; Chen, Y; Carducci, MA; Liu, G; Jarrad, DF; Hahn, NM
  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR
  • Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomized, open-label, phase 3 trial
    Gravis, G; Fizazi, K; Joly, F; Oudard, S; Priou, F; Esterni, B
  • Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
    Sweeney, CJ; Chen, Y; Carducci, M; Liu, G; Jarrad, DF; Eisenberger, M
  • Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
    Fizazi, K; Tran, N; Fein, N; Matsubara, N; Rodriguez-Antolin, A; Alekseev, BY
  • Abiraterone for prostate cancer not previously treated with hormone therapy
    James, ND; de Bono, JS; Gannon, M; Clarke, N
  • Enzalutamide with standard first-line therapy in metastatic prostate cancer
    Davis, ID; Martin, AJ; Stockler, MR; Begbie, S; Chi, KN; Chowdhury, S
  • ARCHES: a randomized, phase 3 study of androgen deprivation therapy eith enzalutamide or placebo in men with metastatic hormone-Sensitive prostate cancer
    Armstrong, AJ; Szmulewitz, RZ; Petrylak, DP; Holzbeierlein, J; Villers, A; Azad, A
  • Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    Fizazi, K; Tran, N; Fein, L; Matsubara, N; Rodriguez- Antolin, A; Alekseev, BY
  • Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
    Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; Attard, G
  • Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Parker, C; Castro, E; Fizazi, K; Heidenreich, A; Ost, P; Procopio, G
  • Chinese expert consensus on the diagnosis and treatment of castration-resistant prostate cancer (2019 update)
    Zhu, Y; Ye, D
  • Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial
    Penson, DF; Armstrong, AJ; Concepcion, R; Agarwal, N; Olsson, C; Dunshee, LK
  • Enzalutamide in Men with nonmetastatic, castrotion-resistant prostate cancer
    Hussain, M; Fizazi, K; Saad, F; Rathenborg, P; Shore, N; Ferreira, U
  • The IMAAGEN study: effect of abiraterone acetate and prednsone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer
    Ryan, CJ; Crrawford, ED; Shore, ND; Underwood, W; Taplin, M; Londhe, A
  • Darolutamide in nonmetastatic, castration-resistant prostate cancer
    Fizazi, K; Shore, N; Tammela, TL; Ulys, A; Vjaters, E; Polyakov, S
  • Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
    Uemura, H; Matsushima, H; Kobayashi, K; Mizusawa, H; Nishimatsu, H; Fizazi, K
  • Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management
    Sountoulides, P; Rountos, T
  • Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis
    Zhu, J; Liao, R; Su, C; Liang, D; Wu, J; Qiu, K
  • Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort
    Ferriero, M; Mastroianni, R; De Nunzio, C; Cindolo, L; Calabro, F; Tema, G
  • Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalcutamide, enzalutamide, or chemotherapy
    Pilon, D; Behl, AS; Ellis, LA; Robitaille, M; Lefebvre, P; Dawson, N
  • Abiraterone acetate plus prednisone versus placebo plu prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study
    Charles, RJ; Smith, MR; Fizazi, K
  • Enzalutamide in metastatic prostate cancer before chemotherapy
    Beer, TM; Armstrong, AJ; Rathkopf, DE
  • Enzalutamide in men with chemotherapy- naïve metastatic castration-resistant prostate cancer: Extended analysis of the phase 3 PREVAIL study
    Beer, TM; Armstrong, AJ; Rathkopf, D; Loriot, Y; Sternberg, CN; Higano, CS
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Tannock, IF; de Wit, R; Berry, WR; Horti, J; Pluzanska, A; Chi, KN
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multientre, open-label, early-access protocol trial
    Sternberg, CN; Castellano, D; Daugaard, G; Geczi, L; Hotte, SJ; Mainwaring, PN
  • Increased survival with enzalutamide in prostate cancer after chemotherapy
    Scher, HI; Fizazi, K; Saad, F; Taplin, M; Sternberg, CN; Miller, K
  • Prednsione plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial
    de Bono, JS; Oudard, S; Ozguroglu, M; Hansen, S; Machiels, J; Kocak, I
  • Third-line enzalutamide following docetaxel and abiraterone in metastatic castrate-resistant prostate cancer
    Davies, RS; Smith, C; Lester, JF
  • Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
    de Wit, R; de Bono, J; Sternberg, CN; Fizazi, K; Tombal, B; Wulfing, C
  • Optimizing the management of castration-resistant prostate cancer patients: a practical guide for clinicians
    Shore, ND; Drake, CG; Lin, DW; Ryan, CJ; Stratton, KL; Dunshee, C
  • Sequencing of agents in castration-resistant prostate cancer
    Lorente, D; Mateo, J; Perez-Lopez, R; de Bono, JS; Attard, G
  • Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance
    Mezynski, J; Pezaro, C; Bianchini, D; Zivi, A; Sandhu, S; Thompson, E
  • The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer
    Schweizer, MT; Zhou, XC; Wang, H; Bassi, S; Carducci, MA; Eisenberger, MA
  • Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment
    Aggarwal, R; Harris, A; Formaker, C; Small, EJ; Molina, A; Griffin, TW
  • A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer
    Azad, AA; Leibowitz-Amit, R; Eigl, BJ; Lester, R; Wells, JC; Murray, RN
  • Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
    Loriot, Y; Bianchini, D; Ileana, E; Sandhu, S; Patrikidou, A; Pezaro, C
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    Noonan, KL; North, S; Bitting, RL; Armstrong, AJ; Ellard, SL; Chi, KN
  • Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abirateron
    Schrader, AJ; Boegemann, M; Ohlmann, CH; Schnoeller, TJ; Krabbe, LM; Hajili, T
  • Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
    Bianchini, D; Lorente, D; Rodriguez-Vida, A; Omlin, A; Pezaro, C; Ferraldeschi, R
  • Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, FB; Røder, MA; Rathenborg, P; Brsso, K; Borre, M; Iversen, P
  • Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
    Badrising, S; van der Noort, V; van Oort, IM; van den Berg, HP; Los, M; Hamberg, P
  • Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients
    Azad, AA; Eigl, BJ; Murray, RN; Kollmannsberger, C; Chi, KN
  • Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents
    Pezaro, CJ; Omlin, AG; Altavilla, A; Lorente, D; Ferraldeschi, R; Bianchini, D
  • Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer
    Sella, A; Sella, T; Peer, A; Berger, R; Frank, SJ; Gez, E
  • CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
    Wissing, MD; Coenen, JL; van den Berg, P; Westgeest, HM; van den Eertwegh, AJM; van Oort, IM
  • Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies
    Al Nakouzi, N; Le Moulec, S; Albigès, L; Wang, C; Beuzeboc, P; Gross- Goupil, M
  • Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with Abiraterone acetate plus prednisone for ≥ 24 week in Europe
    de Bono, JS; Chowdhury, S; Feyerabend, S; Elliott, T; Grande, E; Melhem-Bertrandt, A
  • Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment
    Attard, G; Borre, M; Gurney, H; Loriot, Y; Andresen-Daniil, C; Kalleda, R
  • Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicenter, randomized, open-label, phase 2, crossover trial
    Khalaf, D; Annala, M; Taavitsainen, S; Finh, DL; Oja, C; Vergidis, J